Premium
Psoriasis vulgaris treated successfully with mycophenolate mofetil
Author(s) -
Haufs Mg,
Stefan Beissert,
Stephan Grabbe,
Bärbel Schütte,
T.A. Luger
Publication year - 1998
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.1998.02048.x
Subject(s) - mycophenolate , psoriasis , medicine , mycophenolic acid , immunosuppressive drug , psoriasis area and severity index , transplant rejection , pharmacology , drug , dna synthesis , transplantation , dermatology , immunology , dna , biology , biochemistry
Mycophenolate mofetil (MMF) is a new immunosuppressive drug which non‐competitively and reversibly blocks the de novo synthesis of guanine nucleotides required for DNA and RNA synthesis during T‐ and B‐cell proliferation. This induces a selective inhibition of lymphocyte proliferation. Thus MMF is currently used to prolong graft survival in renal transplant patients. In this communication we describe the first case of a man with severe psoriasis treated successfully with oral MMF without short‐term side‐effects. The psoriasis area and severity index score decreased during therapy (5 weeks) from 22.0 to 11.4. Thus MMF appears to be an effective therapeutic alternative in the treatment of severe psoriasis.